BioSpace News Archive

Surgalign Holdings, Inc. announced its HOLO Portal surgical guidance system won the 2022 Best New Spine Technology Award presented by Orthopedics This Week, the most widely read publication in the orthopedics industry.

Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn” or the “Company”), today announces that it is changing its name to Eterna Therapeutics Inc. (“Eterna”) to reflect its focus on developing advanced therapies using its extensively patented in-licensed mRNA cell engineering technologies.

Allogene Therapeutic today launched CAR T Together™, a first-of-its-kind effort comprised of leading clinical trial investigators who represent the field of clinicians committed to supporting the development of “off-the-shelf” (allogeneic) chimeric antigen receptor (CAR) T products to make CAR T therapy scalable and more accessible to patients with certain cancers.

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to provide an update to its shareholders.

Beckman Coulter Diagnostics, a global leader in clinical diagnostics, announced it acquired StoCastic, LLC., a leading artificial intelligence company that provides evidence-based decision support for hospital emergency departments.

Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022.

HeartBeam, Inc. today announced the appointment of Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer.

Great Bay Bio (hereinafter referred to as “GBB”) today announces the official launch of its self-developed AI-enabled site-specific integration platform for cell line development (CLD), AlfaCell®.

VigiLanz, a clinical software surveillance company, has announced the launch of a new solution that will empower researchers to accurately identify more eligible candidates for clinical trial enrollment in near real time.

PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended its drug discovery collaboration with the Company aimed at identifying potential novel drug candidates for the treatment of severe neuropsychiatric disorders.